Display options
Cite
Barć P, Antkiewicz M, Śliwa B, et al. Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus. J Cardiovasc Transl Res. 2020;14(3):409-415doi: 10.1007/s12265-020-10066-9.
Barć, P., Antkiewicz, M., Śliwa, B., Frączkowska, K., Guziński, M., Dawiskiba, T., Małodobra-Mazur, M., Witkiewicz, W., Kupczyńska, D., Strzelec, B., Janczak, D., & Skóra, J. P. (2021). Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus. Journal of cardiovascular translational research, 14(3), 409-415. https://doi.org/10.1007/s12265-020-10066-9
Barć, Piotr, et al. "Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus." Journal of cardiovascular translational research vol. 14,3 (2021): 409-415. doi: https://doi.org/10.1007/s12265-020-10066-9
Barć P, Antkiewicz M, Śliwa B, Frączkowska K, Guziński M, Dawiskiba T, Małodobra-Mazur M, Witkiewicz W, Kupczyńska D, Strzelec B, Janczak D, Skóra JP. Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus. J Cardiovasc Transl Res. 2021 Jun;14(3):409-415. doi: 10.1007/s12265-020-10066-9. Epub 2020 Sep 01. PMID: 32875492; PMCID: PMC8219552.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Transl Res. 2021 Jun;14(3):409-415. doi: 10.1007/s12265-020-10066-9. Epub 2020 Sep 01.

Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus.

Journal of cardiovascular translational research

Piotr Barć, Maciej Antkiewicz, Barbara Śliwa, Katarzyna Frączkowska, Maciej Guziński, Tomasz Dawiskiba, Małgorzata Małodobra-Mazur, Wojciech Witkiewicz, Diana Kupczyńska, Bartłomiej Strzelec, Dariusz Janczak, Jan Paweł Skóra

Affiliations

  1. Department and Clinic of Vascular, General and Transplantation Surgery, Jan Mikulicz-Radecki Medical University Hospital, Wroclaw Medical University, Wroclaw, Poland.
  2. Department and Clinic of Vascular, General and Transplantation Surgery, Jan Mikulicz-Radecki Medical University Hospital, Wroclaw Medical University, Wroclaw, Poland. [email protected].
  3. Department of Radiology, Jan Mikulicz-Radecki Medical University Hospital, Wroclaw Medical University, Wroclaw, Poland.
  4. Molecular Techniques Unit, Wroclaw Medical University, Wroclaw, Poland.
  5. Regional Specialized Hospital in Wroclaw, Research and Development Center, Wroclaw, Poland.

PMID: 32875492 PMCID: PMC8219552 DOI: 10.1007/s12265-020-10066-9

Abstract

Critical leg ischemia (CLI) complicated by diabetes mellitus (DM), which is a very common and dangerous disease, represents the ultimate stage of peripheral arterial disease. Patients are treated with antiplatelet drugs, statins and limb revascularization, but a significant number of patients are not candidate for revascularization. Literature shows that in such cases, gene therapy could be a perfect therapeutic option. The aim of our study was to evaluate efficacy of double vascular endothelial growth factor/hepatocyte growth factor (VEGF/HGF) gene therapy in patients with CLI complicated by DM. We observed that 90 days after administration, serum level of VEGF and ankle-brachial index increased significantly (p < 0.001) and rest pain decreased significantly compared with the control group (p < 0.002). Moreover considerable improvement in vascularization was observed in computed tomography angiography (P = 0.04). Based on the results of this study, we suggest that the therapy with pIRES/VEGF165/HGF bicistronic plasmid administration is a safe and effective method of treatment of patients with both CLI and DM. Graphical abstract.

Keywords: Critical limb ischemia; Diabetes mellitus; Gene therapy; HGF; VEGF

References

  1. Angiology. 2018 Jul;69(6):465-474 - PubMed
  2. Ann Vasc Surg. 2019 Oct;60:346-354 - PubMed
  3. Cardiovasc Diabetol. 2017 Apr 4;16(1):41 - PubMed
  4. Mol Ther. 2019 Dec 4;27(12):2053 - PubMed
  5. Eur Heart J. 2017 May 7;38(18):1365-1371 - PubMed
  6. Am Heart J. 2011 Mar;161(3):581-9 - PubMed
  7. J Mol Med (Berl). 2019 Feb;97(2):141-151 - PubMed
  8. Hum Gene Ther. 2018 Apr;29(4):413-423 - PubMed
  9. Curr Opin Pharmacol. 2018 Apr;39:60-67 - PubMed
  10. Hum Gene Ther. 2013 Feb;24(2):203-8 - PubMed
  11. Cell Transplant. 2009;18(3):371-80 - PubMed
  12. Expert Opin Biol Ther. 2017 Apr;17(4):449-456 - PubMed
  13. Eur Heart J. 2017 Sep 1;38(33):2547-2555 - PubMed
  14. JAMA Surg. 2016 Nov 1;151(11):1070-1077 - PubMed
  15. Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):20-7 - PubMed
  16. Int Angiol. 2011 Apr;30(2):140-9 - PubMed
  17. Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2503-9 - PubMed
  18. Vascul Pharmacol. 2012 Aug 19;57(1):10-4 - PubMed
  19. J Am Coll Cardiol. 2005 Apr 5;45(7):982-8 - PubMed
  20. Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19 - PubMed
  21. Vascul Pharmacol. 2016 Nov;86:18-30 - PubMed
  22. Gene Ther. 2012 Apr;19(4):392-5 - PubMed
  23. Hum Gene Ther. 2013 Nov;24(11):948-63 - PubMed
  24. Ann Vasc Surg. 2020 Apr;64:228-238 - PubMed
  25. Gene Ther. 2009 May;16(5):629-34 - PubMed
  26. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619877440 - PubMed
  27. Acta Biomater. 2016 Jan;30:1-12 - PubMed

Publication Types